Status:
UNKNOWN
Development and Validation of a Comprehensive Classification Automation System for Kidney Allograft Biopsies
Lead Sponsor:
Paris Translational Research Center for Organ Transplantation
Conditions:
Kidney Transplant Rejection
Pathology
Eligibility:
All Genders
Brief Summary
Since 1991, the Banff classification has been the gold standard for defining antibody-mediated rejection (AMR) and T-cell mediated rejection (TCMR), thereby guiding the treatment and management of tra...
Detailed Description
Despite considerable advances in the development of effective immunosuppressive therapies, allograft rejection remains the main cause of graft loss after kidney transplantation. Since 1991, the Banff ...
Eligibility Criteria
Inclusion
- Kidney transplant recipients
- At least one kidney transplant biopsy performed, assessed with the Banff classification
Exclusion
- Inadequate biopsy according to the Banff classification (number of glomeruli inferior less than seven)
- Missing data for Banff lesion scores
- Missing data for donor-specific antibody status
- Missing data for C4d (degradation product of the classic complement pathway) staining
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT05306795
Start Date
January 1 2016
End Date
December 1 2022
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Paris Translational Centre for Organ Transplantation
Paris, Île-de-France Region, France, 75015